Key Highlights

● Full-year adjusted EPS guidance raised to $5.66 to $5.74

● Board expanded the buyback by $1 billion and extended it through 2027

● Quarterly Dividend of $1.11 yields roughly 5.7% at the current price

● On! nicotine pouch shipments rose 13.3% to 47.8 million cans

Why did Altria Group (NYSE:MO) shares rise on Wednesday, 11 November 2026? The Marlboro maker closed at $77.35 on the New York Stock Exchange, up $1.02 or about 1.3%. The shares traded between $75.53 and $77.46. Altria issued no new press release, SEC filing or guidance change on the day, and no analyst rating change was reported. The move looks like a continuation of the steady buying that has followed the company's third-quarter report and guidance raise on 29 October, amid a broadly positive market.

That market was strong. The S&P 500 rose 1.31% to 7,619.38 as AI stocks rebounded after CoreWeave (NASDAQ:CRWV)'s results, and the consumer staples sector, Altria's group, rose 0.46%. Altria's gain was well ahead of its sector, which suggests its own momentum and income appeal were doing some of the work. The stock's advance has been tied to the higher outlook and buyback expansion from late October, both of which are now old news. The close left Altria about 3% below its 52-week high of $79.87, set on 5 November.

The October results still driving the stock

Altria's third-quarter numbers, filed with the SEC on 29 October, were solid for a Business whose core product is in structural decline. Net revenues rose 1.0% to about $6.13 billion, and revenues net of excise taxes rose 3.6% to about $5.44 billion. Reported diluted EPS was $1.51 and adjusted diluted EPS was $1.52, up 4.8%. Management raised its full-year adjusted diluted EPS guidance to a range of $5.66 to $5.74, which it said represents growth of 4.5% to 6.0% from a 2025 base of $5.42. Chief Executive Sal Mancuso said in the release that "Altria delivered strong financial performance in the third quarter."

Capital return is a large part of the story. Altria bought back 5.9 million shares in the quarter for $400 million, at an average price of $68.52, well below where the stock trades now. Over the first nine months it repurchased 11.2 million shares for $735 million. The board recently expanded the buyback programme by $1 billion and extended it through the end of 2027. The quarterly dividend was raised 4.7% in August to $1.11, an annualised $4.44, and Altria described it as the 61st increase in 57 years. At Wednesday's close that payout works out to a Yield of roughly 5.7%.

The stock gained about 16.5% in October alone and is up more than 40% from its 52-week low of $54.70 in early January. Income-focused coverage has added attention, given the near-6% yield.

What Altria does and why its Revenue per employee is high

Altria is the largest US tobacco company. Through Philip Morris USA it sells Marlboro, the country's best-selling cigarette brand. It also owns U.S. Smokeless Tobacco, maker of Copenhagen and Skoal, Helix Innovations, maker of the on! nicotine pouch, and the NJOY e-vapour business.

Altria ranks 67th among US companies with the highest revenue per employee, at about $3.41 million per employee on roughly 5,900 staff. Two features of the business explain this. First, its revenue line is inflated by federal and state excise taxes collected on each pack: in the third quarter the gap between net revenue and revenue net of excise was nearly $700 million. Second, cigarette Manufacturing is highly automated, distribution runs through wholesalers, and Marketing is heavily restricted by law, so the company needs relatively few people to sell billions of dollars of product. Altria said in its release that it has more than 5,000 employees, small for a company with a Market Value of well over $100 billion.

Valuation and financial position

Before Wednesday's gain, Altria traded at about 15.7 times trailing earnings, with a market value of around $127 billion. On guidance, the shares trade at roughly 13.5 times the midpoint of 2026 adjusted EPS. That is cheap against the S&P 500 but reflects the low-growth, shrinking-volume nature of the core business. The Payout Ratio is about 88.5%, which leaves little room for error but has been supported by heavy, stable free cash flow.

Sector context: Volume decline, pricing power and smoke-free bets

The cigarette business keeps shrinking. Reported domestic cigarette shipments fell 2.9% in the quarter, or about 4% after adjusting for trade inventory, while Altria estimated total industry volume fell about 5%. Marlboro's retail share of the total category slipped 1.0 point to 39.5%, though its share of the premium segment rose to 60.0%. Pricing continues to offset falling volume: adjusted Operating Income for smokeable products rose 3.9%.

The growth bet is in smoke-free products. On! shipments rose 13.3% to 47.8 million cans, giving it an 8.3% share of oral tobacco, although adjusted operating income for oral tobacco fell 3.7%. NJOY ACE remains off the US market following an International Trade Commission exclusion order, and Altria's guidance assumes it does not return in 2026. Regulation is shifting too. Reports in September said the FDA plans to speed up approvals for vapes and pouches, and that Altria sued the agency over its product review process.

The macro picture cuts both ways. High-yield stocks often compete with bonds, and the 10-year Treasury Yield is close to 5% after a hot October Inflation report, with futures pricing a December Fed hike. That would normally weigh on a bond-like stock. At the same time, Altria's defensive Earnings and buyback support have attracted buyers looking for stability.

Risks

The main risks are an accelerating decline in cigarette volume, especially if consumers under financial pressure trade down to cheaper brands, and slower-than-hoped progress in smoke-free products. Regulatory and litigation risk is ever present, including FDA product standards and the long-running legal fight over NJOY. Higher interest rates could reduce the appeal of the dividend, and with a payout ratio near 90% there is limited cushion if earnings falter.

Buyback Pace and 52-Week High

With the stock close to its 52-week high, the next test is whether it can break above $79.87. Investors will watch the pace of Buybacks under the expanded programme, the next ex-dividend date, any FDA action on pouch and vape approvals, and the 2027 earnings guidance that Altria typically gives with fourth-quarter results early in the new year.